Cidara Therapeutics Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Company name
- Cidara Therapeutics Inc.
- Organisation type
- Industry
- Registered legal name
- CIDARA THERAPEUTICS, INC.
- Registry sponsor category
- Industry
- Website
- https://www.cidara.com/
- Headquarters country
- United States
- Publicly traded (proxy)
- Yes
- Listing at source
- Listed
- SEC filer number (CIK)
- 0001610618
- Legal Entity Identifier (LEI)
- 549300IHQ9Z7RI1X2D22
- Wikidata ID
- Q30268897
Related records
Parent companies (1)
- Merck Ltd. Direct parent
Trials (14)
- A Single Ascending Dose Study of CD101 IV in Healthy Subjects
- A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
- A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
- A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
- An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects
- CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
- FungiScope - A Global Emerging Fungal Infection Registry
- Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
- RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
- Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
- Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects
- Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
- Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
- The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults